There are 2867 resources available
166P - Adjuvant trastuzumab plus pertuzumab (TP) versus trastuzumab (T) alone in patients achieving pathologic complete response after chemotherapy with TP
Presenter: Jee Hung Kim
Session: Poster session 01
167P - The prognostic importance of high HER2 copy numbers and high HER2/CEP17 ratio in trastuzumab-treated early breast cancer
Presenter: Caroline Rönnlund
Session: Poster session 01
168P - Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Presenter: Jens Huober
Session: Poster session 01
169P - Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis
Presenter: Javier Cortés
Session: Poster session 01
170P - Phase II study of camrelizumab plus chemotherapy as neoadjuvant therapy in patients with early triple-negative breast cancer
Presenter: Yongsheng Wang
Session: Poster session 01
171P - Association of breast cancer therapy with cognitive decline in older women with early breast cancer: Findings from the CLIMB study
Presenter: Joosje Baltussen
Session: Poster session 01
172P - Prediction of persistent taxane-induced peripheral neuropathy among early-stage breast cancer survivors using whole-exome sequencing
Presenter: Kristina Engvall
Session: Poster session 01
173P - A deep learning model to predict competing cancer and cardiac risks after anthracycline exposure for early breast cancer
Presenter: Colin Mclean
Session: Poster session 01
174P - Breast cancer (BC) and severe COVID-19 (C-19) outcomes: A matched analysis
Presenter: Mariana Chavez Mac Gregor
Session: Poster session 01
175P - Patients’ experiences of a suppoRted self-manAGeMent pAThway in breast cancer (PRAGMATIC): Quality of life results
Presenter: May Teoh
Session: Poster session 01